Search Results
Jun 04, 2026, 03:03 ET Veeva Summit Previews Falcon and the Path to Agentic Biopharma
More than 2,000 gathered to see the future of industry AI AOP Health, Boehringer Ingelheim, GSK, Haleon, MSD, Novo Nordisk, Roche, Sanofi, and Sobi among leaders sharing strategies to streamline and connect operationsBARCELONA,
More news about: Veeva Systems
Jun 03, 2026, 13:03 ET The CRE Finance Council Announces Its 2026 Class of '20 Under 40'
CounselCapital OneCHRISTOPHER PRATTDirectorJLL Capital MarketsSAMANTHA ROTCHFORDManaging DirectorBDT & MSD PartnersWILL STILESDirectorCitiSAMIR TEJPAULHead of InvestmentsMadison Realty CapitalTo learn
More news about: CRE Finance Council
Jun 01, 2026, 08:00 ET Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema
differentiated small-molecule therapies, and providing superior oral alternatives to biologics. The company was founded by senior R&D leaders from Pfizer, MSD, and Johnson & Johnson, focusing on the JAK-STAT and expanding to TYK2 signaling pathways, and mastering targeted protein degradation.The
More news about: Lynk Pharmaceuticals Co., Ltd.
May 30, 2026, 20:00 ET Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
registrational clinical studies in China. MSD is evaluating 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.About Kelun-BiotechKelun-Biotech
More news about: Kelun-Biotech
May 29, 2026, 23:32 ET The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
registrational clinical studies in China. MSD is evaluating 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.About Kelun-BiotechKelun-Biotech
More news about: Kelun-Biotech
May 28, 2026, 19:26 ET Phanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting
metastatic claudin 18.2-positive pancreatic adenocarcinoma in 2024. In 2023, Phanes entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with pembrolizumab.Phanes is conducting clinical trials with spevatamig in multiple
More news about: Phanes Therapeutics, Inc.
May 26, 2026, 07:00 ET Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors
non-small cell lung cancer and cervical cancer."Under the terms of the Agreement, MSD will provide pembrolizumab to Adcendo, which will be the sponsor of the Phase Ib clinical combination trial. Adcendo and MSD each retain all commercial rights to their respective compounds, including as monotherapy
More news about: Adcendo
May 26, 2026, 07:00 ET Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors
non-small cell lung cancer and cervical cancer."Under the terms of the Agreement, MSD will provide pembrolizumab to Adcendo, which will be the sponsor of the Phase Ib clinical combination trial. Adcendo and MSD each retain all commercial rights to their respective compounds, including as monotherapy
More news about: Adcendo
May 21, 2026, 20:00 ET Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
registrational clinical studies in China. MSD is evaluating 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.
More news about: Kelun-Biotech
May 21, 2026, 10:04 ET Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
registrational clinical studies in China. MSD has initiated 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.About Kelun-BiotechKelun-Biotech
More news about: Kelun-Biotech
May 21, 2026, 09:07 ET Leading Security Technology Provider Launches Advanced Detection Solutions for Law Enforcement, Correctional, Healthcare, and K-12 School Facilities
high-security environments," said Luca Cacioli, CEO at CEIA USA. "The MSD Plus detects all cell phone types, along with other ferrous metal contraband, while maintaining high sensitivity and immunity to external interference."The MSD Plus features a rapid 10-second setup time, up to 60 hours of continuous
More news about: CEIA USA
May 21, 2026, 08:30 ET Merck Manuals Answers Common Questions About Hearing Loss and Dementia
MerckManuals.com.About The Merck Manuals and MSD ManualsFirst published in 1899 as a pocket-sized reference for physicians and pharmacists, The Merck Manual has evolved into one of the world's
More news about: The Merck Manuals
May 20, 2026, 15:30 ET CONITEC abre consulta pública para incluir imunoterapia no SUS para quatro tipos de câncer
40/2026 – câncer de pulmãoSobre a MSDPor mais de 130 anos, a MSD cria invenções para a vida, trazendo ao mercado medicamentos inovadores para combater as doenças mais desafiadoras. MSD é o nome pelo qual é conhecida a Merck & Co. Inc. fora dos Estados
More news about: MSD Brasil
May 20, 2026, 12:51 ET Douglas Elliman Development Marketing Named Exclusive Sales and Marketing Firm for The Residences at The Boca Raton by BDT & MSD Partners
Douglas Elliman Development Marketing, a division of Douglas Elliman, today announced its appointment by BDT & MSD Partners ("BDT & MSD") as the exclusive sales and marketing firm for The Residences at The Boca Raton. The development's Executive Director of Sales is Senada
More news about: Douglas Elliman Development Marketing
May 20, 2026, 09:00 ET Oryx Dental Brings the Future of AI-Powered Pediatric Dental SaaS to the 2026 American Academy of Pediatric Dentistry (AAPD) Annual Session
partially erupted teeth, and the patient experience needs to take into account both the child and their parent or caregiver," said Dr. Rania Saleh, DDS, MSD, Founder and CEO of Oryx. "Our pediatric features are purpose-built for this unique specialty—they're not third-party add-ons or a lightly modified general
More news about: Oryx Dental
May 20, 2026, 09:00 ET Forward Launches Forward Predict to Unlock Autonomous Networking
experiences $14.2M in annual benefits through improved efficiency and security.Backed by A. Capital, Andreessen Horowitz, Goldman Sachs, MSD Partners, Omega Venture Partners, Section 32, and Threshold Ventures, Forward is headquartered in Santa Clara, California. For more information, visit
More news about: Forward Networks, Inc.
May 20, 2026, 09:00 ET Forward Launches Forward Predict to Unlock Autonomous Networking
experiences $14.2M in annual benefits through improved efficiency and security.Backed by A. Capital, Andreessen Horowitz, Goldman Sachs, MSD Partners, Omega Venture Partners, Section 32, and Threshold Ventures, Forward is headquartered in Santa Clara, California. For more information, visit
More news about: Forward Networks, Inc.
May 20, 2026, 08:46 ET A.R.I. Highlights OVO Financing as Drake's Triple-Album Release Spotlights Celebrity-Led Brands
capital raise in November 2025 at a $5 billion valuation, led by Goldman Sachs Alternatives with participation from funds affiliated with BDT & MSD Partners.In another high-profile transaction, e.l.f. Beauty announced an agreement to acquire Rhode for up to $1 billion, representing approximately
More news about: A.R.I.
May 20, 2026, 08:08 ET Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026
progression in patients with advanced renal cell carcinoma (RCC) who received lenvatinib plus pembrolizumab (KEYTRUDA®), Merck's (known as MSD outside of the United States and Canada) anti-PD-1 therapy, versus sunitinib (multiple receptor TKI) in the first-line setting. These findings build
More news about: Eisai Inc.
May 20, 2026, 08:00 ET Merck and eschbach's PMWS Workshop Accelerates Pharma Execution via the "Intelligent Visual Factory"
management systems, today announced that its Founder and CEO, Andreas Eschbach, together with Wincy Fung, AVP of Digital Services at Merck (known as MSD outside the U.S. and Canada), are delivering a workshop at the Pharma Manufacturing World Summit (PMWS).
More news about: eschbach
May 18, 2026, 08:00 ET Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026
December 14, 2023. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada).About XTANDI and the Pfizer/Astellas CollaborationIn October 2009, Medivation, Inc.,
More news about: Astellas Pharma Inc.
May 08, 2026, 06:40 ET The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA
[1] MSD is the tradename of Merck & Co., Inc, Rahway, NJ, USA.[2] KEYTRUDA® (pembrolizumab) is a registered trademark of Merck Sharp & Dohme LLC (MSD), a subsidiary
More news about: Kelun-Biotech
May 06, 2026, 10:54 ET HelloNation Highlights What to Expect During an Orthodontic Consultation, Featuring Expert Orthodontist Dr. Michelle Mathieson, DMD, MSD
multimedia:https://www.prnewswire.com/news-releases/hellonation-highlights-what-to-expect-during-an-orthodontic-consultation-featuring-expert-orthodontist-dr-michelle-mathieson-dmd-msd-302764305.htmlSOURCE
More news about: HelloNation
May 05, 2026, 15:30 ET Dira Paes é anunciada como embaixadora de campanha sobre a Hipertensão Arterial Pulmonar
principais fardos enfrentados no tratamento da HAP.Sobre a MSDPor mais de 130 anos, a MSD cria invenções para a vida, trazendo ao mercado medicamentos inovadores para combater as doenças mais desafiadoras. MSD é o nome pelo qual é conhecida a Merck & Co. Inc. fora dos Estados
More news about: MSD Brasil
May 05, 2026, 06:00 ET Waters Corporation (NYSE: WAT) Reports First Quarter 2026 Financial Results
reported revenue of $61 million in the quarter, compared to $53 million for the first quarter of 2025.Materials Sciences Division (MSD)The Materials Sciences Division – formerly known as TA Division – delivered reported revenue of $79 million in the quarter, compared to $75
More news about: Waters Corporation